$0.81
0.05% today
Nasdaq, Apr 01, 07:16 pm CET
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Coherus BioSciences, Inc. Stock price

$0.81
-0.30 27.30% 1M
-0.23 22.40% 6M
-0.57 41.52% YTD
-1.59 66.38% 1Y
-12.10 93.75% 3Y
-15.41 95.02% 5Y
-29.77 97.36% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.03 3.77%
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Key metrics

Market capitalization $93.53m
Enterprise Value $266.19m
P/E (TTM) P/E ratio 4.63
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.00
P/S ratio (TTM) P/S ratio 0.35
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 3.78%
Revenue (TTM) Revenue $266.96m
EBIT (operating result TTM) EBIT $-98.20m
Free Cash Flow (TTM) Free Cash Flow $-20.44m
Cash position $125.99m
EPS (TTM) EPS $0.17
P/E forward 17.12
P/S forward 0.92
EV/Sales forward 2.62
Short interest 32.76%
Show more

Is Coherus BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Coherus BioSciences, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
267 267
4% 4%
100%
- Direct Costs 123 123
25% 25%
46%
144 144
54% 54%
54%
- Selling and Administrative Expenses 149 149
20% 20%
56%
- Research and Development Expense 88 88
13% 13%
33%
-93 -93
52% 52%
-35%
- Depreciation and Amortization 5.28 5.28
17% 17%
2%
EBIT (Operating Income) EBIT -98 -98
50% 50%
-37%
Net Profit 29 29
112% 112%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Coherus BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coherus BioSciences, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent...
Neutral
Seeking Alpha
22 days ago
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, Immuno-Oncology Marketing Theresa LaVallee - CDO Rosh Dias - CMO Bryan McMichael - CFO Conference Call Participants Srikripa Devarakonda - Truist Securities Yigal Nochomovitz - Citigroup ...
Neutral
GlobeNewsWire
22 days ago
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29% quarter-over-quarter –
More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Denny Lanfear
Employees 228
Founded 2010
Website www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today